TransCode Therapeutics, Inc. (NASDAQ: RNAZ) has entered into an exclusive, worldwide license agreement with Unleash Immuno Oncolytics, Inc., obtaining full rights to develop three drug candidates: UIO-524, UIO-525, and UIO-526. The agreement includes all in-licensed and owned rights previously held by Unleash Immuno Oncolytics, providing TransCode with a comprehensive portfolio of next-generation immuno-oncology assets.
Under the terms of the agreement, Unleash Immuno Oncolytics will receive a one-time payment of 1,136,364 shares of a new series of non-voting convertible preferred stock from TransCode. These shares are convertible into an equal number of common shares and represent 6.8% of TransCode's common stock on a fully diluted basis. The transaction represents a strategic expansion of TransCode's oncology pipeline without ongoing royalty obligations.
The lead candidate in this acquisition, UIO-524, is a next-generation oncolytic adenovirus engineered to selectively replicate in malignant cells and cancer-associated stroma. The drug delivers a multi-cytokine immune-activating payload designed to treat solid tumors, with initial targeting focused on muscle-invasive bladder cancer. This technology represents an innovative approach to cancer treatment that combines direct tumor targeting with immune system activation.
The addition of UIO-524 expands TransCode's oncology pipeline alongside its lead asset, TTX-MC138, which is advancing toward a Phase 2a clinical trial. TTX-MC138 focuses on treating metastatic tumors that overexpress microRNA-10b, a well-documented biomarker of metastasis. TransCode's portfolio now includes multiple first-in-class therapeutic candidates designed to mobilize the immune system to recognize and destroy cancer cells.
For business and technology leaders in the healthcare sector, this development represents significant strategic positioning in the competitive immuno-oncology space. The exclusive global license provides TransCode with full control over development and commercialization of these assets, potentially accelerating their path to market. The transaction structure, utilizing equity rather than cash payments, preserves TransCode's financial resources for continued research and development activities.
The implications for the broader oncology treatment landscape are substantial, as next-generation oncolytic viruses like UIO-524 represent a promising frontier in cancer therapy. These approaches aim to overcome limitations of traditional treatments by specifically targeting cancer cells while activating the body's immune response against tumors. For investors and industry observers, this expansion demonstrates TransCode's commitment to building a diversified portfolio of innovative cancer therapies.
TransCode Therapeutics is a clinical stage company pioneering immuno-oncology and RNA therapeutic treatments for high risk and advanced cancers. Additional information about the company is available at https://www.transcodetherapeutics.com. The latest news and updates relating to RNAZ are available in the company's newsroom at https://ibn.fm/RNAZ.
